New Jersey

  • February 27, 2008

    Saul Ewing Bankruptcy Chair Leads Exodus

    A team of Saul Ewing bankruptcy attorneys has decided to jump ship and join the restructuring team at Cole, Schotz, Meisel, Forman & Leonard PA, in order to represent debtors without any fears of clashing with lender clients.

  • February 26, 2008

    Apotex, Pfizer Make Peace On Generic Neurontin

    Apotex Corp. and Pfizer Inc. have settled all outstanding patent infringement and antitrust litigation over Pfizer's blockbuster epilepsy drug, Neurontin, which had earned the company more than $2 billion a year.

  • February 26, 2008

    Judge Limits Port Authority Sept. 11 Insurance Claims

    The Port Authority of New York and New Jersey can only collect insurance for damage done to one World Trade Center building and to the train station below, not for parts of the property that were covered by other insurance policies, a district court judge has ruled.

  • February 22, 2008

    Prodisc Patient Widens Circle Of Blame

    A patient whose artificial spinal disk malfunctioned is broadening his product liability lawsuit against Synthes Spine Inc., which manufactures and markets the disk, adding as defendants the device's original maker and the investment firm that generated the start-up capital to finance the product's development.

  • February 22, 2008

    Alpharma Loses Bid To Get State Wage Claims Tossed

    A judge has denied a motion by Alpharma Inc. to dismiss part of a proposed class action that alleges the company violated the Fair Labor Standards Act and the New Jersey Wage Collection Law by not paying wages and overtime to sales representatives and regional account specialists.

  • February 21, 2008

    Louisiana Accuses Amgen Of Tying Cancer Drugs

    The state of Louisiana and its health department have accused biotech company Amgen Inc. of using its monopoly in the market for one type of anti-cancer drug to boost the sales of a second anti-cancer drug through tying, in violation of state antitrust laws.

  • February 21, 2008

    Diamond Wholesaler Objects To Fortunoff Sale

    Diamond wholesaler Verstandig & Sons Inc. filed a limited objection on Wednesday to the sale of bankrupt Fortunoff Fine Jewelry and Silverware LLC, alleging that Fortunoff is still in possession of Verstandig property that it intends to sell along with other assets as part of the general sale proposal.

  • February 21, 2008

    Smith & Nephew, Synthes Patent Case Settled

    A federal judge has approved a deal that resolves a patent suit Smith & Nephew Plc filed against Synthes Inc. in 2002 and dissolves a 2006 injunction.

  • February 20, 2008

    Judge Approves Congoleum's Disclosure Statement

    A bankruptcy judge has approved Congoleum Corp.'s disclosure statement, setting the stage for possible approval of the flooring company's reorganization plan later this year.

  • February 20, 2008

    Sandata Loses Bid To Toss Infocrossing Counterclaims

    A district court judge has denied Sandata Technologies' attempt to terminate the antitrust allegations that Infocrossing Inc. asserted in response to Sandata's lawsuit over patents for health care worker monitoring systems.

  • February 20, 2008

    Third Refco Executive Pleads Guilty To Fraud

    Just days after former Refco CEO Philip Bennett pled guilty to playing a role in the fraud that felled the once high-flying brokerage, another former executive has followed suit.

  • February 19, 2008

    Ex-Refco CEO Faces Civil Suit From SEC

    Former Refco Inc. Chief Executive Phillip R. Bennett, who is already facing the possible equivalent of a life sentence after pleading guilty to 20 criminal counts on Friday, was sued by the U.S. Securities and Exchange Commission on Tuesday for concealing Refco's finances from investors.

  • February 19, 2008

    High Court Declines Appeal In Ear-Drop Patent Case

    The United States Supreme Court on Tuesday declined Daiichi Sankyo's request for an appeal of a decision by the U.S. Court of Appeals for the Federal Circuit that reversed Daiichi's initial win in a patent infringement case against Apotex Corp.

  • February 19, 2008

    Chocolate Price-Fixing Suit Filed In Canada

    Four of the world's top candymakers have been hit with a proposed class action in Canada for allegedly fixing the prices of their chocolate products.

  • February 19, 2008

    Ernst & Young Settles Cendant Case For $298M

    Auditing firm Ernst & Young LLP has settled a lawsuit brought by fraud-riddled travel and real estate giant Cendant Corp. for almost $300 million. The accounting firm allegedly failed to detect huge anomalies in company audits, according to a securities filing by a former Cendant subsidiary.

  • February 15, 2008

    State, Federal Regulators To Discuss Smart Grid

    State and federal regulators say they will assemble a collaborative dialogue about the transition to a smart electric grid, FERC announced Thursday.

  • February 15, 2008

    Facing March Trial, Ex-Refco CEO Pleads Guilty

    Former Refco Inc. chief executive Phillip R. Bennett walked out of federal court in Manhattan Friday evening facing the possible equivalent of a life sentence, after pleading guilty to all 20 counts leveled against him by federal prosecutors in a January 2007 indictment.

  • February 14, 2008

    Novartis Hits Teva With Another Lotrel Suit

    Novartis International AG now has two patent suits pending against generics maker Teva Pharmaceuticals USA Inc. over the blockbuster hypertension drug Lotrel, lodging a new complaint after Teva submitted a bid to make its proposed generic in different dosage strengths.

  • February 13, 2008

    Lamisil Poses Serious Health Risks: Report

    Novartis AG's oral fungal infection treatment Lamisil appears to put patients at risk of serious, and even life-threatening, liver, blood and skin problems, an Australian health regulator has reported.

  • February 12, 2008

    Amgen Probe Widens As Former Reps Take Action

    An investigation into Amgen Inc.'s alleged privacy violations has widened as two former sales representatives take legal action against the company, seeking to recover compensation they say they lost after objecting to the way psoriasis drug Enbrel was marketed.